Peginterferon lambda for the treatment of patients admitted to hospital with COVID-19: a phase 2, placebo-controlled randomised trial

Kandel et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2025.08.003, ILIAD Cohort B, NCT04354259, Aug 2025

Outcome

Improvement

Relative Risk · 95% CI

7-point scale

-32%1.32 · 0.60–2.86

00.511.52+

← Peginterferon
Lambda reduces riskIncreased risk →

Worse 7-point scale results with treatment

Not statistically significant · p = 0.49

.hsva .va--anim-stagger :is(.va__row,.plot__row,.va__verdict){opacity:1}.hsva .va--anim .plot__shade{opacity:var(--shade-opacity)}.hsva .va--anim-stagger .ci{transform:translateY(-50%)}.hsva .va--anim-stagger .pt{transform:none}.hsva .va--anim-settle .pt{left:calc(min(var(--pt), 2) / 2 * 100%)}.hsva .va--anim-settle .ci{left:calc(var(--lo) / 2 * 100%);width:calc((var(--hi) - var(--lo)) / 2 * 100%)}

RCT 97 hospitalized COVID-19 patients showing no significant benefit with peginterferon lambda.

Important missing comments or errors? Let us know.

risk of 7-point scale, 31.6% higher, OR 1.32, p = 0.49, treatment 48, control 46, inverted to make OR<1 favor treatment, day 14, RR approximated with OR.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Kandel et al., 14 Aug 2025, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, 21 authors, trial NCT04354259 (history) (ILIAD Cohort B).

Late treatment
is less effective